The Cutaneous Connection: Rebuilding the Extracellular Matrix in Wound Healing and Aesthetics

Welcome back to The Cutaneous Connection!

Listen to The Cutaneous Connection on the go on Spotify and Apple Podcasts.

In this episode, Miles Harrison, president and CEO of Conexeu Sciences, and Brian Pilcher, PhD, chief medical officer, discussed the company's investigational extracellular matrix (ECM)-based regenerative platform, its scientific foundation, and its potential to address unmet needs in wound care and aesthetic dermatology.

The executives explained that Conexeu's technology is designed to restore the ECM—the structural scaffold that supports healthy tissue—rather than simply replace lost volume. Unlike traditional hyaluronic acid fillers and biostimulatory injectables, which primarily focus on contour correction and volumization, the company's bio-regenerative approach aims to create an environment that supports cellular migration, tissue ingrowth, and remodeling. The thermosensitive ECM material is reconstituted at the point of care, injected as a liquid, and transitions into a localized gel at body temperature, where it serves as a scaffold for the body's natural regenerative processes.

Although the platform has potential applications across multiple specialties, Conexeu is initially pursuing wound care as its regulatory pathway through the US Food and Drug Administration's 510(k) process for Class II medical devices. Harrison noted that establishing a commercial and regulatory foundation in wound healing could facilitate expansion into additional indications, including medical aesthetics. The executives highlighted the relevance of wound healing biology to dermatology, particularly in procedures such as Mohs surgery, where tissue regeneration plays a central role.

The discussion also explored the growing demand for regenerative therapies in aesthetics, particularly as increasing numbers of patients experience significant weight loss associated with glucagon-like peptide-1 (GLP-1) receptor agonists. Harrison explained that rapid weight loss can lead not only to facial volume depletion but also to deterioration of the ECM, producing changes in tissue quality that may not be adequately addressed with conventional fillers alone. Conexeu believes regenerative approaches may eventually complement existing aesthetic treatments by targeting the underlying tissue framework.

Pilcher emphasized that the technology builds on more than a decade of research in regenerative medicine and tissue engineering and remains investigational. The company recently completed a 12-month proof-of-concept study evaluating tissue remodeling, persistence, inflammatory response, and mechanical properties, though detailed findings have not yet been released pending peer review. Looking ahead, Harrison and Pilcher envision the platform supporting future applications in aesthetics, reconstructive surgery, dentistry, and other areas where restoration of healthy tissue architecture may improve clinical outcomes.

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at [email protected].